Table IV.
Association between subtype of EGFR/KRAS mutation and expression of VEGFA, VEGFR1 and VEGFR2 in lung adenocarcinoma.
| Mutant EGFR | Mutant KRAS | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| EGFR 19 exon | EGFR 20 exon | EGFR 21 exon | KRAS 2 exon | ||||||
| Protein | No. | No. (%) | P-value | No. (%) | P-value | No. (%) | P-value | No. (%) | P-value |
| VEGFA | |||||||||
| Positive | 140 | 28 (20.0) | 0.420 | 12 (8.6) | 0.033 | 41 (29.3) | 0.002 | 14 (10.0) | 0.618 |
| Negative | 64 | 16 (25.0) | 1 (1.6) | 6 (9.4) | 5 (7.8) | ||||
| VEGFR1 | |||||||||
| Positive | 141 | 22 (15.6) | 0.008 | 7 (5.0) | 0.233 | 36 (25.5) | 0.206 | 16 (11.3) | 0.114 |
| Negative | 63 | 20 (31.7) | 6 (9.5) | 11 (17.5) | 3 (4.8) | ||||
| VEGFR2 | |||||||||
| Positive | 98 | 23 (23.5) | 0.526 | 7 (7.1) | 0.665 | 23 (23.5) | 0.776 | 12 (12.2) | 0.166 |
| Negative | 106 | 21 (19.8) | 6 (5.7) | 24 (22.6) | 7 (6.6) | ||||
| VEGFA/VEGFR1a | |||||||||
| Positive | 87 | 14 (16.1) | 0.101 | 8 (9.2) | 0.792 | 30 (34.5) | <0.001 | 12 (13.8) | 0.058 |
| Negative | 117 | 30 (25.6) | 7 (6.0) | 17 (14.5) | 7 (6.0) | ||||
| VEGFA/VEGFR1/VEGFR2b | |||||||||
| Positive | 53 | 9 (17.0) | 0.345 | 4 (7.5) | 0.689 | 15 (28.3) | 0.290 | 9 (16.7) | 0.035 |
| Negative | 151 | 35 (23.2) | 9 (6.0) | 32 (21.2) | 10 (6.6) | ||||
a
Positive expression of VEGFRA/VEGFR1 was defined as the expression of VEGFRA and VEGFR1 in a sample
b
Positive expression of VEGFA/VEGFR1/VEGFR2 was defined as the co-expression of VEGFA, VEGFR1 and VEGFR2 in a sample. EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor.